The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Asylia Therapeutics, Inc.
Honoraria - Abbvie; Adaptive Biotechnologies; Asylia Therapeutics, Inc.; Regeneron; Sanofi; Sporos Bio; Takeda
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Asylia Therapeutics, Inc.; Regeneron; Sanofi; Sporos Bio; Takeda
Research Funding - Asylia Therapeutics, Inc.; BioTheryX; Bristol-Myers Squibb; Heidelberg Pharma
Patents, Royalties, Other Intellectual Property - Asylia Therapeutics, Inc.
Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).
 
Sheeba K. Thomas
Consulting or Advisory Role - Cellectar; MustangBio
Research Funding - Acerta Pharma/AstraZeneca; Ascentage Pharma; Bristol-Myers Squibb; Cellectar; Genentech; Sanofi
 
Jamie S George
No Relationships to Disclose
 
Claudia M Morales de Partovi
No Relationships to Disclose
 
Lei Feng
No Relationships to Disclose
 
Ashley S Morphey
No Relationships to Disclose
 
Melody R. Becnel
No Relationships to Disclose
 
Gregory P Kaufman
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
 
Hans C. Lee
Consulting or Advisory Role - Abbvie; Allogene Therapeutics; Bristol Myers Squibb; Genentech; GlaxoSmithKline; Janssen Research & Development; Regeneron; Sanofi; Takeda
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Regeneron; Takeda
 
Elisabet Esteve Manasanch
Honoraria - Adaptive Biotechnologies; Amgen; BMS; Genentech; GlaxoSmithKline; Legend Biotech; Millennium; Novartis; Pfizer; Sanofi; Takeda; TeloGenomics
Research Funding - GlaxoSmithKline; Quest Diagnostics; Sanofi
 
Krina K. Patel
Consulting or Advisory Role - Abbvie; Arcellx; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Cellectis; Janssen; Karyopharm Therapeutics; Merck; Pfizer; Takeda
Research Funding - Abbvie/Genentech; Allogene Therapeutics; Celgene/Bristol-Myers Squibb; Cellectis; Janssen; Nektar; Precision Biosciences; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Oren Pasvolsky
No Relationships to Disclose
 
Jing Christine Ye
Research Funding - Janssen
 
Behrang Amini
No Relationships to Disclose
 
Muzaffar H. Qazilbash
Research Funding - Angiocrine Bioscience; Janssen; NexImmune; Sanofi
 
Qaiser Bashir
Research Funding - GlaxoSmithKline; Pfizer; Stemline Therapeutics
 
Brandon N Crumpton
No Relationships to Disclose
 
Mildred M Stafford
No Relationships to Disclose
 
Ralph J Johnson III
No Relationships to Disclose
 
Donna M Weber
No Relationships to Disclose
 
Robert Z Orlowski
No Relationships to Disclose